Arca Biopharma Stock Short Ratio
| ABIO Stock | USD 3.65 0.20 5.80% |
ARCA Biopharma fundamentals help investors to digest information that contributes to ARCA Biopharma's financial success or failures. It also enables traders to predict the movement of ARCA Stock. The fundamental analysis module provides a way to measure ARCA Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARCA Biopharma stock.
ARCA | Short Ratio |
ARCA Biopharma Company Short Ratio Analysis
ARCA Biopharma's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current ARCA Biopharma Short Ratio | 7.31 X |
Most of ARCA Biopharma's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARCA Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ARCA Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for ARCA Biopharma is extremely important. It helps to project a fair market value of ARCA Stock properly, considering its historical fundamentals such as Short Ratio. Since ARCA Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ARCA Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ARCA Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
ARCA Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, ARCA Biopharma has a Short Ratio of 7.31 times. This is 87.44% higher than that of the Biotechnology sector and about the same as Health Care (which currently averages 7.41) industry. The short ratio for all United States stocks is 82.75% lower than that of the firm.
ARCA Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARCA Biopharma's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ARCA Biopharma could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics of similar companies.ARCA Biopharma is currently under evaluation in short ratio category among related companies.
ARCA Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of ARCA Biopharma from analyzing ARCA Biopharma's financial statements. These drivers represent accounts that assess ARCA Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ARCA Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.5M | 18.9M | 29.9M | 34.2M | 24.5M | 33.6M | |
| Enterprise Value | (793.8K) | (29.8M) | (23.1M) | (8.0M) | (12.6M) | (12.0M) |
ARCA Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in ARCA Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ARCA Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ARCA Biopharma's value.| Shares | Northern Trust Corp | 2023-12-31 | 21 K | Charles Schwab Investment Management Inc | 2023-12-31 | 15 K | Two Sigma Securities, Llc | 2023-12-31 | 12.1 K | Tower Research Capital Llc | 2023-12-31 | 3 K | Ubs Group Ag | 2023-12-31 | 1.1 K | Parallel Advisors, Llc | 2023-12-31 | 244 | Simplex Trading, Llc | 2023-12-31 | 100.0 | Wells Fargo & Co | 2023-12-31 | 79.0 | Royal Bank Of Canada | 2023-12-31 | 56.0 | Cable Car Capital Llc | 2023-12-31 | 4 M | Western Standard Llc | 2023-12-31 | 1.4 M |
ARCA Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 12.15 M | ||||
| Shares Outstanding | 14.5 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 71.80 % | ||||
| Number Of Shares Shorted | 195.73 K | ||||
| Price To Earning | (0.63) X | ||||
| Price To Book | 1.27 X | ||||
| EBITDA | (7.3 M) | ||||
| Net Income | (5.34 M) | ||||
| Cash And Equivalents | 46.44 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 280 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 16.97 X | ||||
| Book Value Per Share | 2.55 X | ||||
| Cash Flow From Operations | (5.01 M) | ||||
| Short Ratio | 7.31 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 50.03 M | ||||
| Total Asset | 37.86 M | ||||
| Retained Earnings | (188.74 M) | ||||
| Working Capital | 36.95 M | ||||
| Current Asset | 5.88 M | ||||
| Current Liabilities | 26.61 M | ||||
| Net Asset | 37.86 M |
About ARCA Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARCA Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARCA Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARCA Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with ARCA Stock
| 0.71 | ELYM | Eliem Therapeutics | PairCorr |
Moving against ARCA Stock
| 0.87 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.78 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.74 | ALKS | Alkermes Plc Earnings Call Next Week | PairCorr |
| 0.72 | PCRX | Pacira Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.7 | PFE | Pfizer Inc Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ARCA Biopharma Piotroski F Score and ARCA Biopharma Altman Z Score analysis. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.